UY26146A1 - Utilización de ácidos tranexamico para la preparación de una composición de fibrinógeno humano ley 17.164 - Google Patents

Utilización de ácidos tranexamico para la preparación de una composición de fibrinógeno humano ley 17.164

Info

Publication number
UY26146A1
UY26146A1 UY26146A UY26146A UY26146A1 UY 26146 A1 UY26146 A1 UY 26146A1 UY 26146 A UY26146 A UY 26146A UY 26146 A UY26146 A UY 26146A UY 26146 A1 UY26146 A1 UY 26146A1
Authority
UY
Uruguay
Prior art keywords
composition
preparation
law
human fibrinogen
human
Prior art date
Application number
UY26146A
Other languages
English (en)
Inventor
Pere Ristol Debart B Rodriguez
Ma Isabel Bravo Camison
Jesus Fernandez Rodriguez
Pere Ristol Debart
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of UY26146A1 publication Critical patent/UY26146A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invención se refiere a una utilización del ácido tranexámico para la preparación de una composición de fibrinógeno humano obtenido a partir de plasma humano o mediante métodos de tecnología recombinante o transgénica, con la adición simultánea de albúmina humana, para acortar el tiempo de solubilización al anadir un disolvente fisiológicamente compatible y a la composición de fibrinógeno.
UY26146A 1999-05-31 2000-05-16 Utilización de ácidos tranexamico para la preparación de una composición de fibrinógeno humano ley 17.164 UY26146A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009901175A ES2156731B1 (es) 1999-05-31 1999-05-31 Utilizacion del acido tranexamico para la preparacion de una composicion de fibrinogeno humano.

Publications (1)

Publication Number Publication Date
UY26146A1 true UY26146A1 (es) 2000-12-29

Family

ID=8308626

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26146A UY26146A1 (es) 1999-05-31 2000-05-16 Utilización de ácidos tranexamico para la preparación de una composición de fibrinógeno humano ley 17.164

Country Status (7)

Country Link
EP (1) EP1057490A3 (es)
JP (1) JP2001019644A (es)
AR (1) AR024551A1 (es)
ES (1) ES2156731B1 (es)
HU (1) HUP0001841A2 (es)
SK (1) SK7582000A3 (es)
UY (1) UY26146A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2214967B1 (es) * 2003-03-06 2005-06-16 Probitas Pharma, S.A Procedimiento para la eliminacion de virus en soluciones de fibrinogeno y fibrinogeno obtenido por dicho procedimiento.
RU2484817C1 (ru) * 2012-03-11 2013-06-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Астраханская государственная медицинская академия" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО АГМА Минздравсоцразвития России) Способ профилактики повышенной кровопотери и коагулопатического кровотечения при вагинальном родоразрешении в раннем послеродовом периоде
EP2695605B1 (en) * 2012-08-07 2017-05-03 Parapharm Development Ltd. Tranexamic acid composition
KR101841587B1 (ko) * 2016-01-12 2018-05-14 주식회사 녹십자홀딩스 피브리노겐의 정제방법
CA3073685A1 (en) * 2017-08-27 2019-03-07 Anti-Viral Technologies, Llc Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics
CN116115561A (zh) * 2023-03-17 2023-05-16 湖南浩森制药有限公司 一种氨甲环酸注射液及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2101811B (en) * 1981-06-30 1985-01-03 Racal Dana Instr Ltd Improvements in and relating to the screening of electrical circuit arrangements
DE3203775A1 (de) * 1982-02-04 1983-08-11 Behringwerke Ag, 3550 Marburg Fibrinogenzubereitung, verfahen zu ihrer herstellungund ihre verwendung
EP0691858B1 (en) * 1993-03-30 1999-12-15 Omrix Biopharmaceuticals S.A. Two component fibrin glue
GB9424732D0 (en) * 1994-12-08 1995-02-08 Common Services Agency Heat treated blood plasma proteins
EP0856317A1 (en) * 1997-01-31 1998-08-05 Omrix Biopharmaceuticals S.A. A stabilized mixture comprising fibrinogen
WO1998055140A1 (en) * 1997-06-05 1998-12-10 Omrix Biopharmaceuticals S.A. Fibrinogen concentrate from human plasma

Also Published As

Publication number Publication date
HUP0001841A2 (en) 2002-09-28
ES2156731A1 (es) 2001-07-01
AR024551A1 (es) 2002-10-16
ES2156731B1 (es) 2002-02-16
HU0001841D0 (en) 2000-07-28
JP2001019644A (ja) 2001-01-23
EP1057490A3 (en) 2002-04-03
EP1057490A2 (en) 2000-12-06
SK7582000A3 (en) 2001-05-10

Similar Documents

Publication Publication Date Title
ES2539812T3 (es) Péptidos derivados de PRAME y composiciones inmunogénicas que comprenden los mismos
CY1110602T1 (el) Φαρμακευτικες συνθεσεις υπο μορφη γελης ή διαλυματος με βαση τη διυδροτεστοστερονη, μεθοδοι παρασκευης και χρησεις τους
ECSP034430A (es) Esteres oxigenados de acidos 4-yodo fenilamino benzhidroxamcios
PE20110236A1 (es) Proteccion y mejoramiento de celulas, tejidos y organos que responden a la eritropoyetina
NO20010062D0 (no) Bifenylsulfonamider som duale angiotensin-endotelin- reseptorantagonister
BRPI0409133A (pt) formulações farmacêuticas contendo metilnaltrexona
ATE411082T1 (de) Neue verwendung von kurzkettigen carbonsäuren
DE68903846D1 (de) Neue galenische form von fenofibrat.
RS54275B1 (sr) Vodeni 2,6-diizopropilfenol farmaceutski sastavi
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
HK1046004A1 (en) Recombinant gelatins
MX9204625A (es) Composicion farmaceutica para el tratamiento de una especie de mamifero, que sufre de deficiencia cardiaca congestiva.
BR0209685A (pt) Derivado de um peptìdeo insulinotrópico e sais farmaceuticamente aceitáveis produzidos a partir do mesmo, método de produção de derivado de peptìdeo insulinotrópico e uso de um derivado de peptìdeo insulinotrópico e de sais farmaceuticamente aceitáveis
BRPI0514411B8 (pt) formulação, e, método de produzir uma formulação
BR9810478A (pt) Análogos de hormÈnio glicoproteìna reticulados por dissulfeto e sua preparação e utilização
ES2175825T3 (es) Antitraspirante con dibencilidensorbitol.
ATE211391T1 (de) Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung
ES2156642T3 (es) Composicion que comprende un derivado de acido cinamico y un polimero poliaminado.
UY26146A1 (es) Utilización de ácidos tranexamico para la preparación de una composición de fibrinógeno humano ley 17.164
FR2825621B1 (fr) Composition cosmetique pour les ongles, sans phtalate, sans camphre ni solvant aromatique
ITTO20000674A0 (it) Composizioni a base di aminoacidi, atte al trattamento dell'insufficienza cardiaca.
EA200100853A1 (ru) Резорциновая композиция
BRPI0406734A (pt) Composição termiticida, e, método para controlar térmitas
ATE408619T1 (de) Lh-rh-antagonisten, deren herstellung und verwendung als arzneimittel
ATE408415T1 (de) Inhibitoren für die gefässneubildung

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20101201